Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.54 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | SLCO1B1 | Q9Y6L6 | 4/20 | 0.34 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.33 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.32 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ANPEP | P15144 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27033054 | 1.00 | BTK (0.54) | BTKHSD11B1HSD17B10SLCO1B1ASGR1 | |
| SCHEMBL181714 | 0.92 | BTK (0.44) | BTKHSD11B1HSD17B10ASGR1SMN1; SMN2 | |
| SCHEMBL16513085 | 0.92 | BTK (0.44) | BTKHSD11B1HSD17B10ASGR1SMN1; SMN2 | |
| SCHEMBL1663087 | 0.92 | BTK (0.44) | BTKHSD11B1HSD17B10ASGR1SMN1; SMN2 | |
| SCHEMBL2847124 | 0.92 | BTK (0.44) | BTKHSD11B1HSD17B10ASGR1SMN1; SMN2 | |
| SCHEMBL25250119 | 0.87 | HSD11B1 (0.42) | BTKHSD11B1HSD17B10ASGR1KMT2A | |
| SCHEMBL25294971 | 0.87 | HSD11B1 (0.42) | BTKHSD11B1HSD17B10ASGR1KMT2A | |
| SCHEMBL25227942 | 0.86 | BTK (0.55) | BTKHSD11B1HSD17B10SMN1; SMN2KMT2A | |
| SCHEMBL17008904 | 0.85 | BTK (0.41) | BTKHSD11B1ASGR1KAT8SMN1; SMN2 | |
| SCHEMBL28927597 | 0.85 | BTK (0.41) | BTKHSD11B1ASGR1KAT8SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109715609-B | Cyclohexylbenzamide compounds | 伊莱利利公司 | 2023-01-10 | — | — | CN | disclosed |
| US-11214562-B2 | Cyclohexyl benzamide compounds | ELI LILLY AND COMPANY (US) | 2022-01-04 | — | — | US | disclosed |
| US-20210292302-A1 | CYCLOHEXYL BENZAMIDE COMPOUNDS | ELI LILLY AND COMPANY | 2021-09-23 | — | — | US | disclosed |
| EP-3487840-B1 | CYCLOHEXYL BENZAMIDE COMPOUNDS | LILLY CO ELI (US) | 2021-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292302-A1 | CYCLOHEXYL BENZAMIDE COMPOUNDS | CBR1, CNR1, IDH1 | BTK 1859/4885HSD11B1 1661/4885HSD17B10 1403/4885 |
| US-11214562-B2 | Cyclohexyl benzamide compounds | CBR1, CNR1, IDH1 | BTK 1859/4885HSD11B1 1661/4885HSD17B10 1403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.